866-997-4948(US-Canada Toll Free)

Welchol (Type 2 Diabetes) Analysis and Forecasts to 2020

Published By :

GlobalData

Published Date : Oct 2011

Category :

Diabetes

No. of Pages : 33 Pages


Summary

GlobalDatas pharmaceuticals report, Welchol (Type 2 Diabetes) Analysis and Forecasts to 2020 provides Welchol sales estimates for US. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2008-2020). The report also includes information on Type 2 Diabetes market. This report is built using data and information sourced from GlobalDatas proprietary databases, primary and secondary research using Companys corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.

Note: This is a on-demand report and will be delivered within 2 business days (excluding weekends) of the purchase.

Scope
  • Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)
  • Analysis and review of Welchol including historical sales data
  • Qualitative and quantitative assessment of market space
  • Analysis of the trends, drivers and restraints shaping and defining the markets
  • In-depth analysis of Welchol including efficacy, safety, pricing, competition and other details which influence its sales potential
  • Detailed sales forecast for 2008-2020 for Welchol in the US market
Reasons to buy
  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of competition by understanding the changing competitive landscape
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of the drugs performance 
  • Examine the historical sales performance of a drug in seven major markets
  • Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets
Table of Contents

1 Table of Contents 2
1.1 List of Tables 3
1.2 List of Figures 3

2 Introduction 4
2.1 Diabetes Market 4
2.2 Epidemiology 4
2.2.1 Prevalence 4
2.2.2 Mortality 6
2.3 Etiology and Risk Factors 8
2.3.1 Obesity 8
2.3.2 Sedentary Lifestyle 8
2.3.3 Family History and Genetics 8
2.3.4 Ethinicity 8
2.3.5 Old Age 8
2.4 Economic Impact of Diabetes 8
2.5 GlobalData Report Guidance 10

3 Type 2 Diabetes: Market Characterization 11
3.1 Type 2 Diabetes Market 11
3.2 Type 2 Diabetes Market Forecasts and CAGR 12
3.3 Type 2 Diabetes Market: Drivers and Restraints 13
3.3.1 Drivers 13
3.3.2 Restraints 14

4 Classification of Diabetes 15
4.1 Types of Diabetes 15
4.1.1 Type1 Diabetes 15
4.1.2 Type 2 Diabetes 15
4.1.3 Gestational Diabetes 15
4.2 Diabetes Complications 15
4.2.1 Cardiovascular Disease 15
4.2.2 Nephropathy 16
4.2.3 Neuropathy 16
4.2.4 Amputation 16
4.2.5 Retinopathy 16

5 Evolution of Anti-Diabetic Treatments 17

6 Medications 18

6.1 Insulin 18
6.2 Oral Medications 18
6.2.1 Sulfonylureas (SUR) 18
6.2.2 Biguanides (BGDs) 19
6.2.3 Alpha-Glucosidase Inhibitors (AGI) 20
6.2.4 20
6.2.5 Meglitinides 20
6.2.6 Thiazolidinediones (TZDs) 21
6.2.7 Dipeptidyl Peptidase IV (DPP-4) Inhibitors 22
6.2.8 Oral Combination Therapy 22
6.3 Other Injectionable Medications 22
6.3.1 Pramlintide 22
6.3.2 Exenatide 22
6.4 Market Share as per Classes in Type 2 Diabetes 23

7 Welchol 24
7.1 Introduction 24
7.2 Mechanism of Action 24
7.3 Clinical Studies 24
7.4 Approval History of Welchol 25
7.5 Factors Affecting Sales of Welchol 25
7.5.1 Products Uniqueness 25
7.5.2 Low Risk of Cardio Vascular Adverse Events 25
7.5.3 Unmet Need 25
7.5.4 Presence in Market Prior to Type 2 Diabetes 25
7.5.5 Lack of Presence in EU and Japan 26
7.5.6 Safety 26
7.6 Drug Evaluation 26
7.6.1 Drug Risk Benefit Score 26
7.6.2 Intensity of Competition 27
7.7 Sales Forecasts 28
7.7.1 Target Patient Pool 28
7.7.2 Dosing 28
7.7.3 Market Penetration 28
7.7.4 Annual Cost of Therapy 28
7.7.5 Sales Projections of Welchol 28

8 Diabetes Market: Appendix 30
8.1 Market Definitions 30
8.2 List of Abberiviations 30
8.3 Research Methodology 30
8.3.1 Coverage 31
8.3.2 Secondary Research 31
8.3.3 Forecasting 31
8.3.4 Net Penetration of Drug 32
8.3.5 Net Annual Dosing 32
8.3.6 Annual Cost of Therapy 32
8.3.7 Primary Research 32
8.3.8 Expert Panels 32
8.4 Contact Us 33
8.5 Disclaimer 33
8.6 Sources 33

List of Table


Table 1: Diabetes, World, Prevalence Estimates for the age group 20-79 years (million), 2000-2030 4
Table 2: Diabetes, Top 10 Countries, by Prevalence (million), 2010 and 2030 6
Table 3: Diabetes, Top 10 Countries, Highest Health Expenditures ($bn), 2010 9
Table 4: Type 2 Diabetes, World, Major Marketed Drugs 11
Table 5: Type 2 Diabetes, World, Major Pipeline Products in Phase III 12
Table 6: Diabetes, Worldwide, Prevalence Estimates, 2010 and 2030 13
Table 7: Overweight*, Global, Prevalence Estimates in Males Aged 15 and above (%), 2005 14
Table 8: Diabetes Drugs Evolution 17
Table 9: Phase III Trial Results 24
Table 10: Approval of Welchol 25
Table 11: Drug Risk Benefit Score of Welchol 26
Table 12: Welchol, Type 2 Diabetes, The US, Sales Estimates ($m), 2008-2020 29

List of Chart


Figure 1: Diabetes, World, Comparative Prevalence in Age Group 20-79 years (in %), 2010 5
Figure 2: Diabetes, World, Comparative Prevalence in Age Group 20-79 years (in %), 2030 5
Figure 3: Diabetes, World, Mortality, 2010 6
Figure 4: Top 10 Causes of Mortality, Worldwide, 2008 7
Figure 5: Type 2 Diabetes, Global, Market Size Forecasts ($bn), 20102020 12
Figure 6: Mechanism of Action of Sulfonylurea 18
Figure 7: Mechanism of Action of Biguanide, Thiazolidinediones, Alpha-Glucosidase Inhibitors 19
Figure 8: Mechanism of Action of Metformin and Alpha-Glucosidase Inhibitors 20
Figure 9: Mechanism of Action of Thiazolidinediones 21
Figure 10: Mechanism of Action of DPP-IV Inhibitors 22
Figure 11: Type 2 Diabetes, Global, Market Share by Value, By Class (%), 2010 23
Figure 12: Welchol, Type 2 Diabetes, The US, Sales Estimates ($m), 2008-2020 29

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *